Generic Name: ranolazine
Brand Name: TBC
Manufacturer: KYE Pharmaceuticals Inc.
Indications: Stable angina pectoris, adults
Manufacturer Requested Reimbursement Criteria1: Indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists). Ranolazine may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input open | July 17, 2020 |
| Call for patient input closed | September 08, 2020 |
| Clarification: - No patient input submission received | |
| Submission received | August 17, 2020 |
| Submission accepted | August 31, 2020 |
| Review initiated | September 01, 2020 |
| Clarification: - Selected for CADTH/INESSS Joint Clinician Engagement | |
| Draft CADTH review report(s) provided to sponsor for comment | November 16, 2020 |
| Deadline for sponsors comments | November 25, 2020 |
| CADTH responses on draft review report(s) provided to sponsor | January 08, 2021 |
| Expert committee meeting (initial) | January 20, 2021 |
| Draft recommendation issued | February 01, 2021 To February 03, 2021 |